Odyssey Health (ODYY) Income from Continuing Operations (2014 - 2026)
Odyssey Health's (ODYY) quarterly Income from Continuing Operations came in at 825105.0 in Q2 2026, down 333.24% year-on-year from 353758.39 in Q2 2025, and down 38.82% quarter-over-quarter from 594371.0 in Q1 2026.
Odyssey Health (ODYY) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Odyssey Health's Income from Continuing Operations history runs 13 years deep, the most recent figure standing at 825105.0 for Q2 2026.
- On a quarterly basis, Income from Continuing Operations fell 333.24% year-over-year to 825105.0 in Q2 2026; TTM through Apr 2026 was 2032585.0, a 124.59% decrease from a year earlier, with the FY2025 full-year figure at 1273269.0, up 52.1% from the prior year.
- Income from Continuing Operations fell to 825105.0 in Q2 2026 per ODYY's latest filing, from 594371.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 153644.0 in Q3 2024 and bottomed at 3099222.0 in Q2 2022.
- The 5-year median for Income from Continuing Operations is 736656.5 (2024), against an average of 1005144.78.
- Across the five-year window, Income from Continuing Operations surged 112.11% in 2024 and plunged 333.24% in 2026, its largest moves.
- Year by year, Income from Continuing Operations stood at 2149106.0 in 2022, then soared by 74.96% to 538100.0 in 2023, then slipped by 20.46% to 648208.0 in 2024, then soared by 38.52% to 398526.0 in 2025, then slumped by 107.04% to 825105.0 in 2026.
- Per Business Quant, the three latest ODYY Income from Continuing Operations figures stand at 825105.0 (Q2 2026), 594371.0 (Q1 2026), and 398526.0 (Q4 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 380.70 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 199.50 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 273.95 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Odyssey Health | 1.08 Mn | 782,508.17 | - | -825,105.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -825,105.00 |
| Jan 31, 2026 | -594,371.00 |
| Oct 31, 2025 | -398,526.00 |
| Jul 31, 2025 | -214,583.00 |
| Apr 30, 2025 | -190,450.00 |
| Jan 31, 2025 | -220,024.00 |
| Oct 31, 2024 | -648,208.00 |
| Jul 31, 2024 | 153,644.00 |
| Apr 30, 2024 | -474,598.00 |
| Jan 31, 2024 | -1.30 Mn |
| Oct 31, 2023 | -538,100.00 |
| Jul 31, 2023 | -1.27 Mn |
| Apr 30, 2023 | -1.28 Mn |
| Jan 31, 2023 | -1.68 Mn |
| Oct 31, 2022 | -2.15 Mn |
| Jul 31, 2022 | -1.18 Mn |
| Apr 30, 2022 | -3.10 Mn |
| Jan 31, 2022 | -2.18 Mn |
| Oct 31, 2021 | -1.65 Mn |
| Jul 31, 2021 | -2.58 Mn |